SAN DIEGO, Oct. 5, 2015 /PRNewswire/ -- OncoSec Medical
Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, announced today that
CEO and President Punit Dhillon will
present at two high-profile investment conferences in October:
Aegis Capital Corp. 2015 Growth Conference and 14th Annual BIO
Investor Forum.
Aegis Capital Corp. 2015 Growth Conference
Mr. Dhillon will present a corporate overview at the Aegis
Capital Corp. 2015 Growth Conference on October 8 at 4:00 PM
PT located in Brahms 2 at The Encore at Wynn Las Vegas. To
join the live webcast, please access the following link at the time
of the presentation: http://wsw.com/webcast/aegis2/oncs. An
archived version of the webcast will be available for 90 days on
OncoSec's website: http://www.oncosec.com.
The conference is expected to bring more than 100 presenting
companies and more than 500 individuals together for three days of
one-on-one meetings and various networking events. The conference
serves as a platform for individuals in the healthcare, technology,
telecom, and aerospace-defense sectors to network and discuss
innovations in their respective fields. For more information,
please visit: http://www.aegiscapcorp.com/.
14th Annual BIO Investor Forum
Mr. Dhillon will present a corporate overview at the 14th Annual
BIO Investor Forum on October 21 at
9:30 AM PT at Parc 55 San
Francisco.
The forum is an international biotech investor conference
focused on early and established private companies as well as
emerging public companies. The event features plenary sessions,
business roundtables and therapeutic workshops, company
presentations, and one-on-one meetings. For more information,
please visit:
https://www.bio.org/events/conferences/14th-annual-bio-investor-forum.
About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based
intratumoral immunotherapies with an investigational technology,
ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is
designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as IL-12. In Phase I and II clinical
trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety
profile and evidence of anti-tumor activity in the treatment of
various skin cancers as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse™
IL-12, is currently in Phase II development for several
indications, including metastatic melanoma, squamous cell carcinoma
of the head and neck, and triple-negative breast cancer. In
addition to ImmunoPulse™ IL-12, the Company is also identifying and
developing new immune-targeting agents for use with the
ImmunoPulse™ platform. For more information, please visit
www.oncosec.com.
Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-to-present-at-investment-conferences-in-october-300153858.html
SOURCE OncoSec Medical Incorporated